International Myeloma Foundation
Patient Handbook
Multiple Myeloma
Cancer of the Bone Marrow
Korean Language Edition








,



. , .






,

.
, --.
, .
.
.

, , 10


.






.
.
.

.
,
.
.

.

.

,
.
, 10 .
, .

.
.
, .
.
,
.
.
.

?
,
,
.

.


.
,
.
,
.
, .
, . ,

.
. .


.
1.
? ?
2.
? ?
3.
?
4.
?
5.
?
.
.

?
?
13,500
20% 1% .
1/100,000 4/100,000
. .
3 2 , ,

.,
55 . ,
, , , ,
.

?
(plasma cell).






.



( : myeloma cell)
.
. ( )
. (:)
,

.
.











.
(multiple) "myelo"
" omas" .
.,
DNA
.

.


5%


.
,30% 90%
,
.



(


.) .

.
, .
,
. ,, , .

.

.
.
. IL-1,IL-6,TNF
(cytokine) , (osteoclast)
. 30%
X .








(osteoporosis)
(lytic lesion) .



(pathological fracture) .
,
, .


, , .
, .
.
.
. ,
.





. , / ,
()

.



.
( :hypercalcemia) , , ,
.
.

.

? ?


/

.
.


.

(:biopsy)
.
.
(bone marrow)
10% 30% .
:(=kappa) (=lambda)
L- (light chain)/

.
( direct biopsy)

. 90~100%
,
.
(Supportive findings)
30%
.
I/ (M-
)( :staging test ).
IIX .
(lytic lesions) .
(MRI), MIBI FDG/PET

.

. (MGUS)
(smoldering myeloma) .

.

. (monoclonal protein)
(auto-immone disease)(: :systemic lupus
erythematosis , :scleroderma) (: :multiple
sclerosis, : amyotrophic lateral sclerosis[ALS])
. .
(Solitary plasmacytoma).
.

. ( )
. ,
.
. ,
. ,
.
(Monoclonal Gammopathy of Undetermined
Significance : MGUS).
(10% 20% ),
.( 0% ). ,
, . MGUS

, . 2
.
, 10 30% .
MGUS

.

(Indolent myeloma).
MGUS . ,
.
.
(Smoldering myeoloma).

MGUS . .
(STAGING AND PROGNOSTIC FACTORS)
.
1. ?
Durie-Salmon (Staging
System) . ,


.
Stage I
( ) Stage III()
A( )
B( ) . :
Stage I A- , .
Stage III B- , .
Stage III , Stage III B
. .
2. ?
,
. .

,



(labeling
index)
.serum
-2
microglobulin ,
(Bone marrow chromosome test)


. 11 ,13 ,14 ,
. 5 7


,



(myelodyplastic
syndrome:MDS) (stem cell) .
, ,
(amyloid deposits) .
H-(heavy chain) L-( light chain)
.

:
IgG: k lambda
IgG: k lambda
k lambda .( :Bence Jonces myeloma)
:
IgD: k lambda
IgM: k lambda
IgE: k lambda
. , lambda
, IgG kappa
, .

?

. .
1.
(STABILIZING)-
.
: .
: (plasmapheresis): .
(hemodialysis): .
(: pamidronate): ,

2.
(PALLIATIVE)-
.
:
:
: .
(Erythropoietin): .
: .
3.
(REMISSION-INDUCING) ­ ,
.
:
:
: .
: .
4. (CURATIVE) ­ , . (
.)
:
: .

.
, .
.
, .

?
.
(CHEMOTHERAPY)
( ) ,



.



.

(
)



, .
,
.
,,
,/ .
/

.







.
( , , )
.
: ,
, , , , ,, , , ,

. .
.
(RADIATION THERAPY)

.
.
.
.
,
,

.
.


.




.

, .


(BONE MARROW TRANSRANT: BMT AND PRERIPHERAL BLOOD
STEM CELL TRANSPLANT: PBSCT)

. ,
.
,
.






. ,
, .









. , (administering treatment)

.

,




.
.
( : allogenic transplant) ( :
autologous
transplant)

.



,

.
(:VAD) .
. . ""
,
.

(
)
(
)
, ,



.




.

,

.
D. (MAINTENANCE THERAPY)
,



.



.
. :
(I)
(Interferon alpha):

.

. , .
,
3 .
(II)
( Steroids ) ( : prednisone
prednisolone): .
3









. ,
.
(III)
( Supportive care measures):
. (bisphos-
phonate)(: clodronate, pamidronate)
,
.
(Erythropoietin)

(hemoglobin)
.
(IV)
(New approaches):
.
prolotol testing
.

(Thalidomide)


,(angioge-
nesis agents) .
.
, () ,
.
( I ): .
/ /
. (local anaesthetic )
.
.
.
(II ) : .

(III) :
.(:)
(IV) : (Bisphosphonates)
.
(V) :
.

. ,
(:ibuprofen) ,
.

?
.
,
.

,

.
.

.







.
. , ,
.
.,
,
. ,

.
, .
.


.





,

.
,
. ,
.
, .
,
.
.
.

?
, ?
.
.
?
?
?
?
? ?
?(: )
?
? ?
?
?
,
.
? ?
?

?
?
?
?
, , , ,
?
?
?
?




. ,
.
.





?

? ?
? ?
? ? ?
? ?
.
,
.
?
?
?
,
. , .
, .
,
.
.
, .

. ,
,
.
,
.

.








. ,
.

, /
. ,
.
,
.
, ,
, , . .
/ .


(Alkylating Agent):melphalan cyclophosphamide
. DNA
.
(Amyloidosis): L-(light chain)(- )
.
- ,
,L-
,, .
(Anemia): .
10G%,13-14G% .
,, .
(Antibody):
.
(Appendicular Skeletal):, ,,
.
(Axial Skeletal):, , .
-(Bence Jence): .
(Beta 2 Microglobulin):
. , .
/ ,
.
10% ,

. ,
. ,
90%
.
(Bisphosphonate): ()

.
(Bone Marrow):
.
(Bone Marrow Aspiration):
.
(Bone Marrow Biopsy):
.
(Bone Marrow Remodeling):
, ,
.
(Calcium): (Matrix) (Hydroxyapatite)
.
(Calcitonin):
.
(Calcitrol): D D

CAT (Computetized Axial Tomography):
.
(Chmotherapy): .
(Clinical Trials): .
(Consolidation Therapy):

.
.
(Coupling):

.
(Creatinine): .
,
.
.
( Cytokine): .
,
.
DEXA(Dual Photon X-ray Absorptionmetry):
X . .
Dexamethasone: .
(dialysis):

.
()(Electrophoresis):
.
.

M-spike .
.
(Erythropoietin): .
,
.
.

.
,

(Hypercalcemia): .
, .
, ,
IV (IV fruid)
,
.
IgG,IgA: .
G A .
(immunoglobulin) H-(heavy
chains)(G

),(lambda)
(kappa)

L-(light
chains) ., H-(:IgG kappa
IgG lambda) . L-
L-(-) .
H(heavy) L(light) ,
H- L- . L-
- .
IgD.IgE: IgG ,IgA .
(Immunofixation): M-(IgG ,IgA lambda
kappa) .
(immunostaining technique). M- H- L-
.
(Induction Therapy):
.
(Interferon):

(cytokine) .
,
.
(Interferon-6):
.
(Lytic Lesion): X
,
.
, .
(Monoclonal) : ()
. ,
(polyclon) . (M-spike)

M-: .
L- . 24
G . 0.1G/24hrs
, (albumin)
.
.
, M-spike, .
MRI (Magnetic Resonance Imaging):X- ,
.
, ,

.
M-spike: M- . Spike M-
(Electrophoresis)
.
(MDR): ,
adriamycin vincristin .
p-glyco ,

, ,
. p-glyco
. (: PSC833
:cyclopsporin analogue)
(Nephelometry):
.( ). ,
.
(Neutropenia): (neutrophils) .
,
(granulocyte)(neutrophils) , Cytoxic
. , , ,
Cytoxic .
(Osteoclast): .
.
,

. , ,


, ,
(Lytic Lesion) .
(Osteoporosis): .
X
.
(Pathological Fractures):
.
(Plasma Cell): .
. ,


,
M- .

. (:
, ,)

(Plasmacytoma): , ,
.
(plasmapheresis):

(Platelet): .
.
, .

Progression-Free Survival:
.
.
(Osteoblast) : .
.
(Osteoid): .
.
(Radiation Therapy):
.
(Red Cells):
. ,
. (Erythropoietin)
. ,
,
.
. , .

,
.
(Response or Remission):
.
(Complete Remission:CR):
.
CS .

,





.
.
. ,
,
.
(Partial Remission:PR):PR CR
.SWOG , 50%~75% ,
50%.
(Stable Disease):
50% .
CR PR ,
.
, , .
/(Skeletal Survey/Metastatic Survey):
,,,,
.
(Serun Osteocalcin):
. .
.
;(Stem cell): ,,
. ,
.

(Thrombocytopenia): .
150, 000-250,000 , , 50.00
. , 10.000 .
(Transplantation):
/ .
,
.
(Allogenic): HLA
. HLA (Histocompata-
bility Locus Antigens) .

(Unrelated Allogenic Transplant) .
(Autologous):
. .
(PBSC):
.
(syngenic): .
(White Cells): .
.(::neutrophils, :
lymphocytes,: monocytes)
, , (neutropenia)
, . G-CSF(:Neupogen)
.


(Amyloidosis): . , congo
red
: , , (Chemistry
panal test)LDH, ,Serum bete 2 microglobulin ,
CRP,
: .
:X , MRI / CT
, MIBI / PET .
: 24 , (Bence-Jones)
(creatinine clearance) .

INTERNATIONAL MYELOMA
FOUNDATION



..
UNITED STATES OF AMERICA
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
U.S.A.
(800)452-CURE
(818)487-7454Fax
E-mail: TheIMF@myeloma.org
UNITED KINGDOM
9 Gayfield Square
Edinburgh EHI-3NT
U.K
0131-557-3332
0131-556-9720Fax
E-mail:TheIMF@myeloma.org.uk
Website:www.myeloma.org.uk
©2001 International Myeloma Foundation.

Document Outline